BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1706483)

  • 1. [Bleomycin and pulmonary function changes in children with malignant lymphomas].
    Kuijten RR; Voûte PA; van Nierop JC; van Leeuwen EF; Griffioen RW; Wagner-Soeters RE
    Ned Tijdschr Geneeskd; 1991 Feb; 135(6):225-8. PubMed ID: 1706483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors.
    Kharasch VS; Lipsitz S; Santis W; Hallowell JA; Goorin A
    Med Pediatr Oncol; 1996 Aug; 27(2):85-91. PubMed ID: 8649325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
    Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late pulmonary toxicity after treatment for Hodgkin's disease.
    Villani F; De Maria P; Bonfante V; Viviani S; Laffranchi A; Dell'oca I; Dirusso A; Zanini M
    Anticancer Res; 1997; 17(6D):4739-42. PubMed ID: 9494599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients.
    Comis RL; Kuppinger MS; Ginsberg SJ; Crooke ST; Gilbert R; Auchincloss JH; Prestayko AW
    Cancer Res; 1979 Dec; 39(12):5076-80. PubMed ID: 91430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbon monoxide diffusing capacity: a reliable indicator of bleomycin-induced pulmonary toxicity.
    Sørensen PG; Rossing N; Rørth M
    Eur J Respir Dis; 1985 May; 66(5):333-40. PubMed ID: 2410287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
    Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
    Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary function in children treated for rhabdomyosarcoma.
    Kaplan E; Sklar C; Wilmott R; Michaels S; Ghavimi F
    Med Pediatr Oncol; 1996 Aug; 27(2):79-84. PubMed ID: 8649324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration].
    Grahmann PR; Brauer M; Hüter L; Sayer H; Neumann R; Braun RK
    Pneumologie; 2005 Nov; 59(11):763-9. PubMed ID: 16385437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary function assessment during bleomycin therapy.
    Lampert-Benignus E; Eichler-Reiss F; Meunier-Carius J; Keiling R
    Biomed Pharmacother; 1985; 39(2):87-93. PubMed ID: 2410052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
    Kamieńska E
    Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of age on treatment results in children and adolescents with Hodgkin's disease].
    Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
    Przegl Lek; 2004; 61 Suppl 2():40-4. PubMed ID: 15686044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
    Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
    Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
    Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
    Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
    J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.